Navigation Links
Cellectis Publishes 2010 Financial Results
Date:3/31/2011

PARIS, March 31, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

Main financial items:

  • Total operating revenues increased by 55% between 2009 and 2010, from EUR 10.1M to EUR 15.8M. Growth was mainly driven by the increase in the Credit d'Impot Recherche, as a result of several major contracts (Boehringer Ingelheim, Bayer Healthcare and BASF Plant Science) and also by the consolidation of existing partnerships.

  • The development of subsidiaries and acquisition of complementary technologies led to an increase in operating expenses, totaling EUR 27.2M, up 37% from 2009.  

  • The net loss reached EUR 8M, slightly lower than the loss published for 2009, on a comparable basis.

  • The cash position came to EUR 24M at the end of 2010. Its evolution vs. 2009 was, for a third, due to temporary or non-recurring reasons: i/ the temporary augmentation of working capital requirement (Credit d'Impot Recherche increased by EUR 5M), and ii/ the acquisition of CytoPulse Inc.'s patents for EUR 1.5M.

  • Commenting on these results, Marc Le Bozec, Cellectis Chief Financial Officer, explained that "2010 was a year marked by the expansion of our technology and the development of our organization to support our research and marketing efforts. We significantly increased the sales effort of Cellectis bioresearch, formally structured our activities in the area of agrobiotechnology, and secured access to technologies that will help us to shorten the timeframe for bringing products into the market in the coming months."

    Key figures(based on IFRS -- International Financial Reporting Standards):

  • The company has decided to present, from now on, complete consolidated results according to IFRS, with more detail than the non-audited cons
    '/>"/>

  • SOURCE Cellectis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
    2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
    3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
    4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
    5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
    6. Cellectis Unveils Its New Corporate Website
    7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
    8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
    9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
    10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
    11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... , June 3, 2015 /PRNewswire/ ... PNK:BNHLF) gab heute bekannt, dass das US-amerikanische ... 9.044.422 erteilt hat, das den Schutz ... Stoffpatent Mycobacterium phlei Zellwand-Nukleinsäurekomplex (MCNA) von ... Präparat für Erkrankungen im Spätstadium entwickelt ...
    (Date:6/3/2015)... (PRWEB) June 03, 2015 Graphite Metallizing ... bushing materials, will be an exhibitor at the ACHEMA ... from June 15 – June 19 and is considered ... the process industry. , Graphite Metallizing will be ... discussing two exciting new business initiatives. The first is ...
    (Date:6/3/2015)... LONDON , June 3, 2015  Bone morphogenetic ... human body. Identified in 1965 by Marshall Urist ... growth factors that induce mesenchymal stem cells to differentiate ... been discovered to date; only BMP 2, 7 and ... play a significant role in bone formation. However, of ...
    (Date:6/3/2015)... BURLINGTON, Mass. , June 3, 2015 ... best-in-class clinical development and comprehensive commercialization services, ... , Ph.D., as President, inVentiv Health Clinical ... Dr. McKelvey is a seasoned veteran within ... background in clinical development, technology and the ...
    Breaking Biology Technology:Telesta Therapeutics gibt Erteilung des MCNA-Stoffpatents durch das US-amerikanische Patent- und Markenamt bekannt 2Telesta Therapeutics gibt Erteilung des MCNA-Stoffpatents durch das US-amerikanische Patent- und Markenamt bekannt 3GRAPHALLOY Exhibiting at the 2015 ACHEMA World Forum 2Bone Morphogenetic Proteins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2022 2Bone Morphogenetic Proteins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2022 3inVentiv Health Names Dr. Michael McKelvey President, Clinical Division And Executive Vice President, inVentiv Health 2inVentiv Health Names Dr. Michael McKelvey President, Clinical Division And Executive Vice President, inVentiv Health 3inVentiv Health Names Dr. Michael McKelvey President, Clinical Division And Executive Vice President, inVentiv Health 4inVentiv Health Names Dr. Michael McKelvey President, Clinical Division And Executive Vice President, inVentiv Health 5
    ... to Membership , , , COLD SPRING HARBOR, ... year agreement with Amerinet Inc. to offer the AccuVein AV300, ... members. The AccuVein AV300 projects a pattern of light ... healthcare professional locate veins for blood draw (venipuncture), IV starts ...
    ... , NEW YORK, June 8 Keryx Biopharmaceuticals, Inc. ... the Phase 2 study of Zerenex (ferric citrate) for ... in patients with end-stage renal disease (ESRD) on thrice ... clinical trial, which enrolled 55 patients. The primary objective ...
    ... , DUROS(R) continuous delivery of exenatide produces impressive reductions ... 28-day treatment , , NEW ORLEANS, June 8 ... first clinical study of ITCA 650 (DUROS(R) continuous delivery ... as a late-breaker at the Annual Conference of the ...
    Cached Biology Technology:AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 5Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4
    (Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
    (Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
    (Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
    Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
    ... Finding cures for hearing loss, breast cancer and childhood ... for tuberculosis are goals of the first recipients of ... Collaborative Research Fund. The fund, a $3 million initiative ... supports collaboration among researchers at Rice University, Texas Children,s ...
    ... three undergraduates set off on an expedition in 1965 to ... realise that they were establishing the groundwork for a study ... led by the University of York has repeated the survey ... moved uphill by about 67 metres over the intervening years ...
    ... COLUMBIA, Mo. When it is head versus heart, ... organ to develop and is critical in supplying blood ... known about the complex processes that regulate the heartbeat. ... has identified certain proteins within the heart muscle that ...
    Cached Biology News:Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4The global impact of climate change on biodiversity 2Researchers examine developing hearts in chickens to find solutions for human heart abnormalities 2
    ... Rabbit polyclonal to MSY2/YBOX2 ( ... Antigen: Synthetic ... to the C-terminus of Human MSY2/YBOX2. ... is proprietary) (Peptide ...
    Request Info...
    Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
    ... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
    Biology Products: